RODMAN&RENSHAW upgraded shares of TuHURA Biosciences (NASDAQ:HURA – Free Report) to a strong-buy rating in a research report released on Thursday morning,Zacks.com reports.
Several other analysts have also commented on the stock. Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a research note on Thursday. They set a “buy” rating and a $11.00 target price for the company. Maxim Group started coverage on TuHURA Biosciences in a research report on Tuesday, November 5th. They set a “buy” rating and a $15.00 price objective for the company.
Check Out Our Latest Stock Report on TuHURA Biosciences
TuHURA Biosciences Stock Performance
TuHURA Biosciences Company Profile
TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
See Also
- Five stocks we like better than TuHURA Biosciences
- How to invest in marijuana stocks in 7 steps
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- Which Wall Street Analysts are the Most Accurate?
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
